BINV Stock Overview A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BioInvent International AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BioInvent International Historical stock prices Current Share Price SEK 28.60 52 Week High SEK 50.80 52 Week Low SEK 15.00 Beta 0.41 1 Month Change -31.25% 3 Month Change -32.55% 1 Year Change 83.33% 3 Year Change -24.42% 5 Year Change -24.44% Change since IPO -97.84%
Recent News & Updates Bioinvent International AB (Publ) Announces Promising Initial Efficacy Data from Triple Combination Arm of Bi-1206, Rituximab and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Bioinvent International AB Appoints Ashley Robinson as SVP Strategy & Finance to Lead U.S. Expansion Dec 03 BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025
Third quarter 2024 earnings released: kr1.48 loss per share (vs kr1.08 loss in 3Q 2023) Nov 01
Insufficient new directors Nov 01
New minor risk - Revenue size Oct 17 See more updates Bioinvent International AB (Publ) Announces Promising Initial Efficacy Data from Triple Combination Arm of Bi-1206, Rituximab and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Bioinvent International AB Appoints Ashley Robinson as SVP Strategy & Finance to Lead U.S. Expansion Dec 03 BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025
Third quarter 2024 earnings released: kr1.48 loss per share (vs kr1.08 loss in 3Q 2023) Nov 01
Insufficient new directors Nov 01
New minor risk - Revenue size Oct 17
Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments Sep 16
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma Sep 12 Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
Second quarter 2024 earnings released: kr2.09 loss per share (vs kr1.34 loss in 2Q 2023) Aug 30
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth? Aug 16
BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application Jul 30
Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024 Jun 26
BioInvent International Gains Patent for BI-1808 in China Jun 25 BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024
Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL May 16
First quarter 2024 earnings released: kr1.18 loss per share (vs kr1.12 loss in 1Q 2023) Apr 24
Price target decreased by 23% to kr83.00 Apr 10
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully Apr 09 BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024
BioInvent International AB (publ), Annual General Meeting, May 03, 2024 Mar 28
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23
BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024 Feb 21
New minor risk - Market cap size Feb 02
BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607 Dec 06
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910 Dec 05
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent Nov 04
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910 Nov 01
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Oct 27
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies Sep 22
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors Sep 08
Independent Director recently bought kr603k worth of stock Sep 03
Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth Sep 01
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 31
New minor risk - Market cap size Aug 16
Independent Director recently bought kr238k worth of stock Jul 16
BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies Jun 21
BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023 Jun 13
BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors Jun 08
BioInvent Ready for Combination Studies with BT-001 Jun 07
Independent Chairman of the Board recently bought kr127k worth of stock Jun 02
Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive Jun 02
Independent Chairman of the Board recently bought kr127k worth of stock May 31
BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs May 24
High number of new directors May 19
Forecast to breakeven in 2025 Apr 27
Full year 2022 earnings: Revenues exceed analyst expectations Apr 08
Forecast to breakeven in 2025 Feb 28
Full year 2022 earnings released: kr0.69 loss per share (vs kr5.14 loss in FY 2021) Feb 28
Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week Feb 25
Forecast to breakeven in 2025 Jan 01 BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023
Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206 Dec 09
BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607 Nov 18
Price target increased to kr113 Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Oct 28
Forecast to breakeven in 2024 Oct 09
We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely Sep 28
Consensus revenue estimates increase by 130% Sep 27
Price target increased to kr112 Sep 26
BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808 Sep 09
CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China Sep 08 BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023 BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023
Consensus forecasts updated Sep 01
Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook Aug 31 Aug 26
Price target increased to kr115 Aug 26
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 25
BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors Aug 02
Bioinvent International Resolves to Elect Natalie Berner and Nanna Lüneborg as New Board Members Jul 13
Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001 Jun 28
Bioinvent International AB (Publ) Appoints Sylvie Ryckebusch as Chief Business Officer Jun 10
Forecast to breakeven in 2023 May 21
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 27
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 11
President & CEO recently bought kr249k worth of stock Mar 12
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 24 BioInvent International AB (publ) to Report Q3, 2022 Results on Oct 27, 2022
Independent Director recently bought kr399k worth of stock Jan 25 Shareholder Returns BINV SE Biotechs SE Market 7D -2.7% 1.5% 1.1% 1Y 83.3% 18.9% 14.0%
See full shareholder returns
Return vs Market: BINV exceeded the Swedish Market which returned 14% over the past year.
Price Volatility Is BINV's price volatile compared to industry and market? BINV volatility BINV Average Weekly Movement 7.4% Biotechs Industry Average Movement 9.8% Market Average Movement 5.6% 10% most volatile stocks in SE Market 12.2% 10% least volatile stocks in SE Market 3.2%
Stable Share Price: BINV has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BINV's weekly volatility (7%) has been stable over the past year.
About the Company BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
Show more BioInvent International AB (publ) Fundamentals Summary How do BioInvent International's earnings and revenue compare to its market cap? BINV fundamental statistics Market cap SEK 1.88b Earnings (TTM ) -SEK 409.65m Revenue (TTM ) SEK 38.64m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BINV income statement (TTM ) Revenue SEK 38.64m Cost of Revenue SEK 0 Gross Profit SEK 38.64m Other Expenses SEK 448.29m Earnings -SEK 409.65m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) -6.23 Gross Margin 100.00% Net Profit Margin -1,060.29% Debt/Equity Ratio 0%
How did BINV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 02:22 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Morten Larsen ABG Sundal Collier Camilla Oxhamre Carnegie Investment Bank AB Mattias Häggblom Danske Bank
Show 6 more analysts 
